Business Wire

NORTHERN-DATA-AG

7.1.2021 09:41:26 CET | Business Wire | Press release

Share
Northern Data acquires data center site in Northern Sweden fully powered by green energy

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) acquires a data center facility in Northern Sweden to meet massive customer demand. The site currently consists of six data center halls on an area of 2.5 hectares and will now be further expanded by Northern Data following the acquisition.

Northern Data's new site is located in the Northern Swedish city of Boden, which has an average annual temperature of 1.3 degrees Celsius due to its location around 80 kilometers south of the Arctic Circle. The location is therefore ideal for passive energy-saving cooling of the HPC hardware.

In addition to the ideal HPC temperature conditions, the region in Northern Sweden is characterized by high connectivity and very cheap regional surplus electricity from renewable energy sources. The electricity for Northern Data's new site is 100 percent sourced from renewable energy, generated by hydropower plants in the region. The local hydropower plants have a capacity of about 4.5 gigawatts (GW), producing about 14 terawatt hours (TWh) per year, which is available to Northern Data at the lowest electricity prices in the EU.

Not least due to the cool air temperatures near the Arctic Circle, an excellent PUE value ("Power Usage Effectiveness") of 1.07 is achieved. The PUE value puts the total energy consumption of a data center in relation to the energy consumption of the IT infrastructure. The closer the value is to 1.0, the more efficient the data center. With a value of 1.07, Northern Data's future data center is among the worldwide leaders and is well below the industry average of 1.67.

The site, which has won awards for its ultra-efficiency, meets the very highest requirements, with various ISO certifications and was completed by data center operator Hydro66 only in 2019. Northern Data will start allocating hardware instantly due to the high demand from its customers and will continue to massively expand the site immediately.

Northern Data CEO Aroosh Thillainathan comments: "Due to the high demand for HPC capacity, we are constantly reviewing options to quickly secure additional sites through acquisitions in addition to building our own data centers. This allows us to further accelerate our growth. In view of this strategy, the new site in Northern Sweden is not only a real stroke of luck but also a significant expansion step for our company. Not only can we use it instantly, but we can also expand and develop it quite considerably, which we will do immediately. Our new site offers important advantages, such as lowest energy costs and ultra-efficiency, which will make it an important part of the Northern Data group going forward."

The acquisition of the entire data center facility, including two operating companies and part of the team, is still subject to, among others, a successful due diligence process and will take place through the issuance of EUR 21 million in shares, subject to a full lock-up period of two years, and a cash component of EUR 4 million.

About Northern Data:

Northern Data AG develops and operates global infrastructure solutions in the field of High Performance Computing (HPC). With its customized solutions, the company provides the infrastructure for diverse HPC applications in areas such as bitcoin mining, artificial intelligence, blockchain, big data analytics, IoT or rendering. The internationally active company is now a leading provider in the field of HPC solutions worldwide. Northern Data offers its HPC solutions both in large, stationary data centers and in mobile high-tech data centers that can be set up at any location worldwide. In doing so, the company combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. Northern Data currently employs around 150 people.

Disclaimer:

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG, nor does it constitute a securities prospectus of Northern Data AG. The information contained in this press release is not intended to be the basis for any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As in all business and investment matters, please consult qualified professional advice.

Language:

English

Company:

Northern Data AG

 

Thurn-und-Taxis-Platz 6

 

60313 Frankfurt/Main

 

Germany

Phone:

+49 69 34 87 52 25

E-mail:

info@northerndata.de

Internet:

www.northerndata.de

ISIN:

DE000A0SMU87

WKN:

A0SMU8

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg,
Hanover, Munich (m:access), Stuttgart, Tradegate Exchange

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye